A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms

E. Piovano, E. Pivetta, P. Modaffari, F. Martra, C. Baima Poma, S. Perotto, E. Tripodi, V. Zanfagnin, P. Zola, A. Ferrero

Research output: Contribution to journalArticle

Abstract

Aims: To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies. Methods: The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features. Results: The incidence of HR was 14% (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02-1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01-0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78-8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94-12.45, p = 0.06, for the taxane model). Conclusion: We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.

Original languageEnglish
Pages (from-to)21-27
Number of pages7
JournalGynecologic and Obstetric Investigation
Volume74
Issue number1
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Female Genital Neoplasms
Pelvic Neoplasms
Paclitaxel
Platinum
Hypersensitivity
Salts
Drug Therapy
Carboplatin
Taxoids
Medical Records

Keywords

  • Chemotherapy
  • Gynecologic pelvic neoplasms
  • Hypersensitivity reactions
  • Paclitaxel
  • Platinum salts

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. / Piovano, E.; Pivetta, E.; Modaffari, P.; Martra, F.; Baima Poma, C.; Perotto, S.; Tripodi, E.; Zanfagnin, V.; Zola, P.; Ferrero, A.

In: Gynecologic and Obstetric Investigation, Vol. 74, No. 1, 07.2012, p. 21-27.

Research output: Contribution to journalArticle

Piovano, E, Pivetta, E, Modaffari, P, Martra, F, Baima Poma, C, Perotto, S, Tripodi, E, Zanfagnin, V, Zola, P & Ferrero, A 2012, 'A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms', Gynecologic and Obstetric Investigation, vol. 74, no. 1, pp. 21-27. https://doi.org/10.1159/000336772
Piovano, E. ; Pivetta, E. ; Modaffari, P. ; Martra, F. ; Baima Poma, C. ; Perotto, S. ; Tripodi, E. ; Zanfagnin, V. ; Zola, P. ; Ferrero, A. / A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. In: Gynecologic and Obstetric Investigation. 2012 ; Vol. 74, No. 1. pp. 21-27.
@article{7ae59cb721a1456b95c53818753a664d,
title = "A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms",
abstract = "Aims: To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies. Methods: The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features. Results: The incidence of HR was 14{\%} (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02-1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01-0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78-8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94-12.45, p = 0.06, for the taxane model). Conclusion: We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.",
keywords = "Chemotherapy, Gynecologic pelvic neoplasms, Hypersensitivity reactions, Paclitaxel, Platinum salts",
author = "E. Piovano and E. Pivetta and P. Modaffari and F. Martra and {Baima Poma}, C. and S. Perotto and E. Tripodi and V. Zanfagnin and P. Zola and A. Ferrero",
year = "2012",
month = "7",
doi = "10.1159/000336772",
language = "English",
volume = "74",
pages = "21--27",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms

AU - Piovano, E.

AU - Pivetta, E.

AU - Modaffari, P.

AU - Martra, F.

AU - Baima Poma, C.

AU - Perotto, S.

AU - Tripodi, E.

AU - Zanfagnin, V.

AU - Zola, P.

AU - Ferrero, A.

PY - 2012/7

Y1 - 2012/7

N2 - Aims: To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies. Methods: The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features. Results: The incidence of HR was 14% (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02-1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01-0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78-8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94-12.45, p = 0.06, for the taxane model). Conclusion: We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.

AB - Aims: To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies. Methods: The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features. Results: The incidence of HR was 14% (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02-1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01-0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78-8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94-12.45, p = 0.06, for the taxane model). Conclusion: We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.

KW - Chemotherapy

KW - Gynecologic pelvic neoplasms

KW - Hypersensitivity reactions

KW - Paclitaxel

KW - Platinum salts

UR - http://www.scopus.com/inward/record.url?scp=84864597197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864597197&partnerID=8YFLogxK

U2 - 10.1159/000336772

DO - 10.1159/000336772

M3 - Article

C2 - 22652565

AN - SCOPUS:84864597197

VL - 74

SP - 21

EP - 27

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 1

ER -